M

Mayinglong Pharmaceutical Group Co Ltd
SSE:600993

Watchlist Manager
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Watchlist
Price: 25.03 CNY -1.8% Market Closed
Market Cap: 10.8B CNY
Have any thoughts about
Mayinglong Pharmaceutical Group Co Ltd?
Write Note

Intrinsic Value

The intrinsic value of one Mayinglong Pharmaceutical Group Co Ltd stock under the Base Case scenario is 30.57 CNY. Compared to the current market price of 25.03 CNY, Mayinglong Pharmaceutical Group Co Ltd is Undervalued by 18%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
30.57 CNY
Undervaluation 18%
Intrinsic Value
Price
M
Worst Case
Base Case
Best Case

Valuation Backtest
Mayinglong Pharmaceutical Group Co Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for Mayinglong Pharmaceutical Group Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about Mayinglong Pharmaceutical Group Co Ltd?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Mayinglong Pharmaceutical Group Co Ltd

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Mayinglong Pharmaceutical Group Co Ltd

Provide an overview of the primary business activities
of Mayinglong Pharmaceutical Group Co Ltd.

What unique competitive advantages
does Mayinglong Pharmaceutical Group Co Ltd hold over its rivals?

What risks and challenges
does Mayinglong Pharmaceutical Group Co Ltd face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Mayinglong Pharmaceutical Group Co Ltd.

Provide P/S
for Mayinglong Pharmaceutical Group Co Ltd.

Provide P/E
for Mayinglong Pharmaceutical Group Co Ltd.

Provide P/OCF
for Mayinglong Pharmaceutical Group Co Ltd.

Provide P/FCFE
for Mayinglong Pharmaceutical Group Co Ltd.

Provide P/B
for Mayinglong Pharmaceutical Group Co Ltd.

Provide EV/S
for Mayinglong Pharmaceutical Group Co Ltd.

Provide EV/GP
for Mayinglong Pharmaceutical Group Co Ltd.

Provide EV/EBITDA
for Mayinglong Pharmaceutical Group Co Ltd.

Provide EV/EBIT
for Mayinglong Pharmaceutical Group Co Ltd.

Provide EV/OCF
for Mayinglong Pharmaceutical Group Co Ltd.

Provide EV/FCFF
for Mayinglong Pharmaceutical Group Co Ltd.

Provide EV/IC
for Mayinglong Pharmaceutical Group Co Ltd.

Show me price targets
for Mayinglong Pharmaceutical Group Co Ltd made by professional analysts.

What are the Revenue projections
for Mayinglong Pharmaceutical Group Co Ltd?

How accurate were the past Revenue estimates
for Mayinglong Pharmaceutical Group Co Ltd?

What are the Net Income projections
for Mayinglong Pharmaceutical Group Co Ltd?

How accurate were the past Net Income estimates
for Mayinglong Pharmaceutical Group Co Ltd?

What are the EPS projections
for Mayinglong Pharmaceutical Group Co Ltd?

How accurate were the past EPS estimates
for Mayinglong Pharmaceutical Group Co Ltd?

What are the EBIT projections
for Mayinglong Pharmaceutical Group Co Ltd?

How accurate were the past EBIT estimates
for Mayinglong Pharmaceutical Group Co Ltd?

Compare the revenue forecasts
for Mayinglong Pharmaceutical Group Co Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Mayinglong Pharmaceutical Group Co Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Mayinglong Pharmaceutical Group Co Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Mayinglong Pharmaceutical Group Co Ltd compared to its peers.

Compare the P/E ratios
of Mayinglong Pharmaceutical Group Co Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Mayinglong Pharmaceutical Group Co Ltd with its peers.

Analyze the financial leverage
of Mayinglong Pharmaceutical Group Co Ltd compared to its main competitors.

Show all profitability ratios
for Mayinglong Pharmaceutical Group Co Ltd.

Provide ROE
for Mayinglong Pharmaceutical Group Co Ltd.

Provide ROA
for Mayinglong Pharmaceutical Group Co Ltd.

Provide ROIC
for Mayinglong Pharmaceutical Group Co Ltd.

Provide ROCE
for Mayinglong Pharmaceutical Group Co Ltd.

Provide Gross Margin
for Mayinglong Pharmaceutical Group Co Ltd.

Provide Operating Margin
for Mayinglong Pharmaceutical Group Co Ltd.

Provide Net Margin
for Mayinglong Pharmaceutical Group Co Ltd.

Provide FCF Margin
for Mayinglong Pharmaceutical Group Co Ltd.

Show all solvency ratios
for Mayinglong Pharmaceutical Group Co Ltd.

Provide D/E Ratio
for Mayinglong Pharmaceutical Group Co Ltd.

Provide D/A Ratio
for Mayinglong Pharmaceutical Group Co Ltd.

Provide Interest Coverage Ratio
for Mayinglong Pharmaceutical Group Co Ltd.

Provide Altman Z-Score Ratio
for Mayinglong Pharmaceutical Group Co Ltd.

Provide Quick Ratio
for Mayinglong Pharmaceutical Group Co Ltd.

Provide Current Ratio
for Mayinglong Pharmaceutical Group Co Ltd.

Provide Cash Ratio
for Mayinglong Pharmaceutical Group Co Ltd.

What is the historical Revenue growth
over the last 5 years for Mayinglong Pharmaceutical Group Co Ltd?

What is the historical Net Income growth
over the last 5 years for Mayinglong Pharmaceutical Group Co Ltd?

What is the current Free Cash Flow
of Mayinglong Pharmaceutical Group Co Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Mayinglong Pharmaceutical Group Co Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Mayinglong Pharmaceutical Group Co Ltd

Current Assets 4.1B
Cash & Short-Term Investments 3B
Receivables 589.6m
Other Current Assets 494.3m
Non-Current Assets 1.1B
Long-Term Investments 151.4m
PP&E 686.1m
Intangibles 196.5m
Other Non-Current Assets 63.3m
Current Liabilities 937.4m
Accounts Payable 210.7m
Accrued Liabilities 126.5m
Short-Term Debt 198.4m
Other Current Liabilities 401.9m
Non-Current Liabilities 400.7m
Long-Term Debt 193.6m
Other Non-Current Liabilities 207.1m
Efficiency

Earnings Waterfall
Mayinglong Pharmaceutical Group Co Ltd

Revenue
3.5B CNY
Cost of Revenue
-1.9B CNY
Gross Profit
1.6B CNY
Operating Expenses
-1B CNY
Operating Income
526.9m CNY
Other Expenses
-44.6m CNY
Net Income
482.4m CNY

Free Cash Flow Analysis
Mayinglong Pharmaceutical Group Co Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

Mayinglong Pharmaceutical Group Co Ltd's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Year Average ROIC
Positive Free Cash Flow
Positive ROIC
60/100
Profitability
Score

Mayinglong Pharmaceutical Group Co Ltd's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Mayinglong Pharmaceutical Group Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Negative Net Debt
Long-Term Solvency
87/100
Solvency
Score

Mayinglong Pharmaceutical Group Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Mayinglong Pharmaceutical Group Co Ltd

Wall Street analysts forecast Mayinglong Pharmaceutical Group Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Mayinglong Pharmaceutical Group Co Ltd is 38.24 CNY with a low forecast of 37.86 CNY and a high forecast of 39.36 CNY.

Lowest
Price Target
37.86 CNY
51% Upside
Average
Price Target
38.24 CNY
53% Upside
Highest
Price Target
39.36 CNY
57% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for Mayinglong Pharmaceutical Group Co Ltd?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for Mayinglong Pharmaceutical Group Co Ltd is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Mayinglong Pharmaceutical Group Co Ltd

Country

China

Industry

Pharmaceuticals

Market Cap

10.8B CNY

Dividend Yield

0%

Description

Mayinglong Pharmaceutical Group Co., Ltd. engages in the manufacture of pharmaceutical products. The company is headquartered in Wuhan, Hubei and currently employs 3,208 full-time employees. The company went IPO on 2004-05-17. The firm's pharmaceutical products are classified as drugs for hemorrhoid, including diosmin tablets, suppositories, pastes and granules, among others; drugs for cough, including levodropropizine oral solution and compound glycyrrhiza oral solution, as well as drugs for skin injuries, including products such as erythromycin ointment. The firm also provides specialty drugs. The firm is also engaged in the production and distribution of eye cream products with the brand named Mayinglong BaBao, as well as the provision of hospital clinical service. The firm distributes its products mainly in domestic markets.

Contact

HUBEI
Wuhan
No. 100, Nanhu Zhoujiawan, Wuchang
+862787291519
www.mayinglong.cn

IPO

2004-05-17

Employees

3 208

Officers

GM & Director
Mr. Youzhang Xia
Finance Director & Accounting Supervisor
Mr. Tao Mao
Deputy GM & Director
Mr. Ping An Liu
Deputy GM & Secretary to the Board of Directors
Ms. Qian Ma

See Also

Discover More
What is the Intrinsic Value of one Mayinglong Pharmaceutical Group Co Ltd stock?

The intrinsic value of one Mayinglong Pharmaceutical Group Co Ltd stock under the Base Case scenario is 30.57 CNY.

Is Mayinglong Pharmaceutical Group Co Ltd stock undervalued or overvalued?

Compared to the current market price of 25.03 CNY, Mayinglong Pharmaceutical Group Co Ltd is Undervalued by 18%.

Back to Top